Skip to Main Content

At a Glance


"Manager/junior staff relations are great"

"Humane, positive, relaxed environment


"The hours can be very volatile, making it hard to make plans in your personal life"

"Thinly staffed"

The Buzz

"Respected in health care"

"Haven't heard of them"

About Leerink Swann LLC

Healthy business

Boston’s Leerink Swann is a specialist boutique that focuses exclusively on the health care industry.  The firm was founded by now-CEO Jeff Leerink in 1995; by 1999, it had landed a spot on Inc. magazine’s America’s 500 Fastest-Growing Private Companies list.  Today, Leerink has offices in Boston, New York and San Francisco; its service lines include investment banking, institutional sales and trading, equity research, strategic consulting, and private and corporate client services.  Leerink’s investment banking professionals offer services related to mergers and acquisitions, public offerings, private placements and private investments in public equity (PIPE) offerings.

Backing the firm’s health care expertise is its MEDACorp network, a brain trust of more than 35,000 physicians, researchers and other health care experts in North America, Europe and Asia.  Leerink professionals work closely with MEDACorp members, who are paid consulting fees for their services, to advise the firm’s clients.  The network is pitched as an opportunity for members to network with clients’ senior executives and health care industry insiders who have the capability to support clinical trials and other research efforts.

To crack down on conflicts of interest, and to maintain its standards for consulting, Leerink regularly audits network members, and denies membership to employees of publicly traded companies and government employees.

Providing it all

Leerink Swann Consultants provides a range of advisory services, working in close collaboration with the firm’s investment banking group; these services include portfolio management and product search processes, like identifying licensing opportunities; corporate strategy development; product and therapeutic area strategy for clinical development, marketing and positioning; and M&A-driven growth and transaction strategies.

A single stake

Leerink has been privately held since its inception, but in 2007, it sold a $35 million minority stake to Los Angeles-based private equity firm Lovell Minnick and fellow i-banking boutique March Group.  Representatives from both investing firms now sit on Leerink’s board of directors.  CEO Jeff Leerink said at the time that the capital would fund expansion efforts.

Research awards galore

Industry publications regularly single out Leerink Swan's research analysts for their stock-picking prowess.  Over the years, the firm's analysts have been given awards and honors by The Wall Street Journal, Thomson Reuters StarMine and the Financial Times, among others.  Leerink Swan's sales team is not slouch, either.  In 2008, it took first place in Institutional Investor’s All-America Institutional Sales Team Healthcare Survey of chief investment officers, portfolio managers, buy-side analysts, research directors and other investment professionals.  Leerink’s sales team also came in No. 2 in the survey's biotechnology category.  The team is certainly no stranger to Institutional Investor kudos, for seven years in a row it was dubbed Best of the Boutiques in multiple health care categories.

Leerink Swann LLC

1 Federal Street
37th Floor
Boston, MA 02110
Phone: (617) 248-1601

Firm Stats

Employer Type: Private
CEO: Jeffrey A. (Jeff) Leerink
2010 Employees (All Locations): 200